Ulcerating necrobiotic xanthogranuloma: A clinical sign to reconsider progression from MGUS to multiple myeloma

• Christopher J. Fay, BA,
• Christopher Iriarte, MD,
• Dorsa Moslehi, BA,
• Jimmy Lam, MD,
• Igor Katsyv, MD, PhD,
• Nicole R. LeBoeuf, MD, MPH

Affiliations

Christopher J. Fay, BA

Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts

Christopher Iriarte, MD

Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Dorsa Moslehi, BA

Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Jimmy Lam, MD

Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Igor Katsyv, MD, PhD

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

Nicole R. LeBoeuf, MD, MPH

Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Correspondence to: Nicole R. LeBoeuf, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, 450 Brookline Ave, Boston, MA 02115.